Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron Phase 2 in Obesity or Overweight
NCT05051579Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of orforglipron in obesity, Overweight, sponsored by Eli Lilly and Company. Started Sep 2021; status: completed.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05051579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05051579.